Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
ADPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.98 - $13.68
Previous CloseN/A
Volume480.81K
Average Volume (3M)2.15M
Market Cap
$1.92B
Enterprise Value$1.79B
Total Cash (Recent Filing)$197.87M
Total Debt (Recent Filing)$84.37M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Oct 30, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding152,273,910
10 Day Avg. Volume1,984,529
30 Day Avg. Volume2,150,165
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue8.73
Enterprise Value/Gross Profit13.22
Enterprise Value/Ebitda-18.17
Forecast
1Y Price Target
$13.75Price Target Upside9.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAdaptive Biotechnologies reported revenues above consensus, driven by strong MRD revenues and clonoSEQ volume growth.
Market MomentumShares of ADPT have outperformed nearly every other name in the sector and are up +107% YTD.
Revenue GrowthRevenues grew 36% and were 19% ahead of expectations, indicating strong business performance.
Strategic FlexibilityThe termination of the agreement with Genentech will be effective on February 9, 2026, after which ADPT will no longer be bound by any exclusivity obligations related to cell therapies in oncology.
Bears Say
Financial RevenueThe company will recognize $33.7 million of noncash revenue from the remaining amortization of the upfront cash consideration.
Partnership ChangesThe termination of the Genentech collaboration gives Adaptive more flexibility as it is released from its obligations related to exclusivity for cell therapies in oncology.
Adaptive Biotechnologies News
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $3.98 and its highest was $13.68 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Adaptive Biotechnologies Corp’s market cap is $1.92B.
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Oct 30, 2025 which is in 44 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on Aug 05, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.239 by $0.069.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -0.18.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 152,273,910 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.239. Following the earnings report the stock price went up 5.792%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Currently, no hedge funds are holding shares in ADPT
Adaptive Biotechnologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.75 (9.04% Upside)
$13.75 (9.04% Upside)
Blogger Sentiment
Bullish
ADPT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
193.25%
12-Months-Change
Fundamentals
Return on Equity
-57.55%
Trailing 12-Months
Asset Growth
-15.09%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies (ADPT) is a biotechnology company specializing in the development of innovative genomic technologies to improve the diagnosis and treatment of diseases, particularly in the fields of oncology and immunology. The company focuses on harnessing the power of the adaptive immune system to create advanced tools for disease detection, monitoring, and therapeutic development. Its core products include its clonoSEQ platform for measuring minimal residual disease in blood cancers and immune profiling services that help in understanding immune responses to various diseases.
ADPT Company Deck
ADPT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong performance in the MRD business with significant revenue growth and profitability, improved gross margins, and successful EMR integrations. Despite high operating expenses and a continued loss in the Immune Medicine segment, the company is optimistic about future growth and has raised its full year guidance.View all ADPT earnings summariesADPT Stock 12 Month Forecast
Average Price Target
$13.75
▲(9.04% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Syndax Pharmaceuticals
―
89bio
―
Pharvaris
―
Immunocore Holdings
―
Ownership Overview
4.46% Insiders
19.56% Mutual Funds
0.23% Other Institutional Investors
59.22% Public Companies and
Individual Investors